According to RadNet's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -124.783. At the end of 2021 the company had a P/E ratio of 64.1.
Year | P/E ratio | Change |
---|---|---|
2021 | 64.1 | -198.21% |
2020 | -65.2 | -193.19% |
2019 | 70.0 | |
2017 | > 1000 | 9.0267497647513E+17% |
2016 | 40.3 | 10.89% |
2015 | 36.4 | -87.23% |
2014 | 285 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Quest Diagnostics
DGX | 17.7 | -114.18% | ๐บ๐ธ USA |
![]() LabCorp LH | 21.8 | -117.50% | ๐บ๐ธ USA |
![]() Psychemedics PMD | -10.8 | -91.38% | ๐บ๐ธ USA |
![]() Enzo Biochem ENZ | -1.48 | -98.81% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.